We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+1.55%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.06T
AUM Growth
-$16.9B
Cap. Flow
-$16.2B
Cap. Flow %
-1.53%
Top 10 Hldgs %
26.1%
Holding
3,048
New
131
Increased
1,029
Reduced
1,524
Closed
112

Top Buys

Rank Stock Value
1
XYZ
Block Inc
XYZ
+$2.39B
2
CVNA icon
Carvana
CVNA
+$1.82B
3
MSFT icon
Microsoft
MSFT
+$1.5B
4
DIS icon
Walt Disney
DIS
+$1.25B
5
SPOT icon
Spotify
SPOT
+$1.05B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$2.65B
2
INTU icon
Intuit
INTU
+$2.08B
3
MTCH icon
Match Group
MTCH
+$1.87B
4
CRM icon
Salesforce
CRM
+$1.76B
5
META icon
Meta Platforms (Facebook)
META
+$1.61B

Sector Composition

Rank Sector Weight
1 Technology 25.08%
2 Healthcare 16.24%
3 Consumer Discretionary 15.33%
4 Communication Services 13.82%
5 Financials 12.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CATX icon
2901
Perspective Therapeutics
CATX
$372M
$39K ﹤0.01%
6,150
CLRB icon
2902
Cellectar Biosciences
CLRB
$20.8M
$39K ﹤0.01%
+139
New +$42.4K
CEMI
2903
DELISTED
Chembio diagnostics, Inc.
CEMI
$38K ﹤0.01%
15,200
TIO
2904
DELISTED
Tingo Group, Inc. Common Stock
TIO
$38K ﹤0.01%
24,300
AUD
2905
DELISTED
Audacy, Inc.
AUD
$37K ﹤0.01%
10,072
-400
-4% -$1.4K
ELOX
2906
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$37K ﹤0.01%
+568
New +$35K
HAACW
2907
DELISTED
Health Assurance Acquisition Corp. Warrants
HAACW
$36K ﹤0.01%
35,000
LPTH icon
2908
Lightpath Technologies
LPTH
$862M
$33K ﹤0.01%
15,300
NAT icon
2909
Nordic American Tanker
NAT
$1.36B
$33K ﹤0.01%
13,062
-400
-3% -$1K
RESN
2910
DELISTED
Resonant Inc.
RESN
$32K ﹤0.01%
13,400
-14,800
-52% -$40.9K
CRBP icon
2911
Corbus Pharmaceuticals
CRBP
$189M
$29K ﹤0.01%
947
ABEO icon
2912
Abeona Therapeutics
ABEO
$425M
$27K ﹤0.01%
+976
New +$31.3K
SONN
2913
DELISTED
Sonnet BioTherapeutics
SONN
$27K ﹤0.01%
18
URG
2914
Ur-Energy
URG
$537M
$27K ﹤0.01%
15,685
YARW
2915
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$27K ﹤0.01%
21
-24
-53% -$46.5K
RGLS
2916
DELISTED
Regulus Therapeutics
RGLS
$26K ﹤0.01%
+3,810
New +$27.9K
NMTR
2917
DELISTED
9 Meters Biopharma
NMTR
$26K ﹤0.01%
991
+75
+8% +$1.77K
EGIO
2918
DELISTED
Edgio, Inc. Common Stock
EGIO
$25K ﹤0.01%
+265
New +$27.9K
EMWP
2919
DELISTED
Eros Media World PLC
EMWP
$25K ﹤0.01%
1,357
-110
-7% -$2.1K
SVRA icon
2920
Savara
SVRA
$1.17B
$24K ﹤0.01%
17,260
EUCRW
2921
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$18K ﹤0.01%
22,697
TNXP icon
2922
Tonix Pharmaceuticals
TNXP
$205M
0
TRVN
2923
DELISTED
Trevena, Inc.
TRVN
$17K ﹤0.01%
22
AFMD
2924
DELISTED
Affimed
AFMD
-4,505
Closed -$383K
AKYA
2925
DELISTED
Akoya BioSciences
AKYA
-500,644
Closed -$9.68M

Similar funds

T. Rowe Price Associates's Q3 2021 Portfolio in Review

As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
  • T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
  • T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
  • T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
  • T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
  • T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.